Over the 52 weeks , hypomagnesemia ( 7.2 % ) was the most common treatment-related adverse event , mild to moderate constipation ( 6.3 % ) was the most common gastrointestinal adverse event , and hypokalemia ( < 3.5 mEq/L ) occurred in 5.6 % of patients .